Cleocin Vaginal Ovules
Name: Cleocin Vaginal Ovules
Microbiology
Clindamycin inhibits bacterial protein synthesis at the level of the bacterial ribosome. The antibiotic binds preferentially to the 50S ribosomal subunit and affects the process of peptide chain initiation. Although clindamycin phosphate is inactive in vitro, rapid in vivo hydrolysis converts this compound to the antibacterially active clindamycin.
Culture and sensitivity testing of bacteria are not routinely performed to establish the diagnosis of bacterial vaginosis. (See INDICATIONS AND USAGE.) Standard methodology for the susceptibility testing of the potential bacterial vaginosis pathogens, Gardnerella vaginalis, Mobiluncus spp, or Mycoplasma hominis, has not been defined. Nonetheless, clindamycin is an antimicrobial agent active in vitro against most strains of the following organisms that have been reported to be associated with bacterial vaginosis:
- Bacteroides spp
- Gardnerella vaginalis
- Mobiluncus spp
- Mycoplasma hominis
- Peptostreptococcus spp
PRINCIPAL DISPLAY PANEL - 100 mg Suppository Foil Carton
NDC 0009-7667-01
Pfizer
Cleocin®
Vaginal Ovules
equivalent to
100 mg*
clindamycin
(clindamycin phosphate
vaginal suppositories)
For Intravaginal Use Only
3 Suppositories with one applicator
Rx only
| CLEOCIN clindamycin phosphate suppository | |||||||||||||
| |||||||||||||
| |||||||||||||
| |||||||||||||
| |||||||||||||
| Labeler - Pharmacia and Upjohn Company LLC (618054084) |
| Establishment | |||
| Name | Address | ID/FEI | Operations |
| Pharmacia and Upjohn Company LLC | 618054084 | ANALYSIS(0009-7667), API MANUFACTURE(0009-7667), LABEL(0009-7667), MANUFACTURE(0009-7667), PACK(0009-7667) | |